Modified Nanoparticles for Lipophilic Toxin Sequestration

Award Information
Agency: Department of Defense
Branch: Air Force
Contract: FA9550-13-C-0007
Agency Tracking Number: F10B-T24-0250
Amount: $749,646.00
Phase: Phase II
Program: STTR
Awards Year: 2013
Solicitation Year: 2010
Solicitation Topic Code: AF10-BT24
Solicitation Number: 2010.B
Small Business Information
AuraSense, LLC
8045 Lamon Avenue, Suite 410, Skokie, IL, -
DUNS: 831421958
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 Weston Daniel
 Research Scientist
 (847) 673-1700
 wdaniel@aurasense.com
Business Contact
 Percy Crocker
Title: VP of Commercial Development
Phone: (847) 673-1702
Email: pcrocker@aurasense.com
Research Institution
 Northwestern University
 Shad Thaxton
 303 E. Superior St.
Robert H. Lurie Building
Chicago, IL, 60611-
 (773) 957-9503
 Nonprofit college or university
Abstract
ABSTRACT: Mycotoxins are toxic secondary metabolites of molds and fungi, many of which are pathogenic to humans. In general, mycotoxins enter the body through the skin, digestive tract, or through respiration. Exposure to a few milligrams can be lethal. Mycotoxins have a high likelihood of being weaponized, due to their ease of large scale production. One possible way to counteract the effect of mycotoxins is to neutralize them by sequestration in lipophilic membranes, apart from cell membranes. Using cholesterol as a safe and relevant model system for sequestering membrane incorporated lipophilic toxins, AuraSense proposes to use lipid and protein-modified gold nanoparticles to develop constructs for the sequestration of toxic lipophilic molecules. In Phase I, AuraSense demonstrated that the mycotoxin binding nanoparticles synthesized were able to sequester the toxin analogue in buffered saline solutions and in in vitro cell culture assays. In Phase II, AuraSense will extend these experiments in to in vivo systems and examine the ability of the nanoparticles to sequester and excrete these toxins. BENEFIT: The key technological objective in this proposal is to demonstrate that a mycotoxin binding platform is a useful therapy for combating the toxic effects of exposure. AuraSense's mycotoxin binding nanoparticles (MB NP) constructs address a key unmet need: the lack of effective agents for transporting lipophilic toxins, such as mycotoxins, safely out of the body. In response to this unmet need, the Company's objective is a medical countermeasure based upon the MB NP platform and tailored for use against major classes of lipophilic toxins in a field setting. Such a product, if properly configured, could prove essential in responding to a particularly dangerous, and plausible, terrorist or foreign military attack.

* information listed above is at the time of submission.

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government